ArticleJournal of orthopaedics2025
Indomethacin versus Ketorolac for the prevention of heterotopic ossification in hip arthroscopy patients.
Article in Journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonsteroidal anti-inflammatory drugs are commonly utilized to reduce the risk of developing heterotopic ossification (HO) after hip arthroscopy. However, it is not known which regimen is optimal. Purpose: The purpose of this study is to determine the rate of HO formation after hip arthroscopy in response to different NSAID protocols. Methods: Consecutive cases of a single fellowship-trained surgeon at a tertiary referral center were retrospectively reviewed. Patients received a regimen of two medications, starting with four days of either Ketorolac or Indomethacin and ending with either Celecoxib, Meloxicam, Diclofenac, or Naproxen. Two reviewers assessed HO on postoperative radiographs. Results: 323 cases were included for retrospective review. 48 (15 %) were found to develop HO after hip arthroscopy. Patients who also underwent labral repair (p = 0.046) and those with larger corrections in alpha angle (p = 0.048) were found to have higher rates of HO. Multivariate regression found that receiving Meloxicam as a second medication was found to have a significantly higher risk of HO than Celecoxib (OR 4.72, p = 0.035). Male gender (OR 2.36, p = 0.013), was also found to be associated with a higher likelihood of HO formation according to the model. Conclusion: While taking Meloxicam as the second NSAID was associated with a significantly higher rate of HO than Celecoxib, no one regimen was found to be superior. Additionally, male gender was found to be a significant predictor of HO development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.